Literature DB >> 19215692

Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure.

K Maeda1, C Hamada, T Hayashi, I Shou, M Wakabayashi, M Fukui, S Horikoshi, Y Tomino.   

Abstract

The oral adsorbent AST-120 has been widely used in Japan to delay the initiation of dialysis therapy in patients with chronic renal failure. This study evaluated the long-term effects of AST-120 in patients with chronic renal failure who had not previously undergone dialysis. One hundred out-patients were prospectively enrolled and prescribed 6 g/day oral AST-120 for >or= 1 year. The clinical effectiveness of AST-120 was evaluated by comparing changes in the slope of the reciprocal serum creatinine-time plot (1/sCr slope) before and after AST-120 administration. The 1/sCr slope improved significantly after >or= 1 year of AST-120 treatment and greatest improvement was observed in patients with the longest AST-120 administration period (> 30 months). The results suggest that long-term treatment with AST-120 may be beneficial for chronic renal failure patients in the pre-dialysis stage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19215692     DOI: 10.1177/147323000903700125

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  13 in total

1.  Long-term effects of AST-120 on the progression and prognosis of pre-dialysis chronic kidney disease: a 5-year retrospective study.

Authors:  Eiichi Sato; Atsushi Tanaka; Jun-Ichi Oyama; Ayumu Yamasaki; Mitsuhiro Shimomura; Atsushi Hiwatashi; Yoshihiko Ueda; Mayuko Amaha; Mayumi Nomura; Daisuke Matsumura; Tsukasa Nakamura; Koichi Node
Journal:  Heart Vessels       Date:  2015-12-23       Impact factor: 2.037

Review 2.  The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective.

Authors:  Paula Mosińska; Martin Storr; Jakub Fichna
Journal:  Therap Adv Gastroenterol       Date:  2015-09       Impact factor: 4.409

3.  Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate.

Authors:  Suree Lekawanvijit; Andrew R Kompa; Minako Manabe; Bing H Wang; Robyn G Langham; Fuyuhiko Nishijima; Darren J Kelly; Henry Krum
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

4.  Effect of an Oral Adsorbent, AST-120, on Dialysis Initiation and Survival in Patients with Chronic Kidney Disease.

Authors:  Shingo Hatakeyama; Hayato Yamamoto; Akiko Okamoto; Kengo Imanishi; Noriko Tokui; Teppei Okamoto; Yuichiro Suzuki; Naoaki Sugiyama; Atsushi Imai; Shigemasa Kudo; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Noritaka Kaminura; Hisao Saitoh; Tomihisa Funyu; Chikara Ohyama
Journal:  Int J Nephrol       Date:  2012-01-12

Review 5.  Non-systemic drugs: a critical review.

Authors:  Dominique Charmot
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 6.  AST-120 for the management of progression of chronic kidney disease.

Authors:  Gerald Schulman; Raymond Vanholder; Toshimitsu Niwa
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-01-30

Review 7.  Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients.

Authors:  Shunsuke Ito; Masayuki Yoshida
Journal:  Toxins (Basel)       Date:  2014-02-20       Impact factor: 4.546

8.  Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea.

Authors:  Ran-Hui Cha; Shin Wook Kang; Cheol Whee Park; Dae Ryong Cha; Ki Young Na; Sung Gyun Kim; Sun Ae Yoon; Sejoong Kim; Sang Youb Han; Jung Hwan Park; Jae Hyun Chang; Chun Soo Lim; Yon Su Kim
Journal:  Kidney Res Clin Pract       Date:  2017-03-31

9.  Effect of AST-120 on Endothelial Dysfunction in Adenine-Induced Uremic Rats.

Authors:  Yuko Inami; Chieko Hamada; Takuya Seto; Yoko Hotta; Seiki Aruga; Jiro Inuma; Kosuke Azuma; Hiroaki Io; Kayo Kaneko; Hirotaka Watada; Yasuhiko Tomino
Journal:  Int J Nephrol       Date:  2014-04-14

10.  Importance of AST-120 (Kremezin®) Adherence in a Chronic Kidney Disease Patient with Diabetes.

Authors:  Yasuhiko Tomino; Atsuko Hisada-Urita; Takuto Seki; Tomonari Watanabe; Reo Kanda; Toshimasa Takahashi
Journal:  Case Rep Nephrol Dial       Date:  2018-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.